Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
2001 2
2007 1
2009 1
2010 1
2011 1
2017 1
2018 1
2021 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Pulmonary lymphadenopathy.
Omlor GJ. Omlor GJ. Pediatr Infect Dis J. 2001 Apr;20(4):437-8. doi: 10.1097/00006454-200104000-00013. Pediatr Infect Dis J. 2001. PMID: 11332671 No abstract available.
Pulmonary lymphadenopathy.
Omlor GJ. Omlor GJ. Pediatr Infect Dis J. 2001 Apr;20(4):436-438. Pediatr Infect Dis J. 2001. PMID: 11373545 No abstract available.
Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trial.
Gifford AH, Odem-Davis K, Kloster M, O'Sullivan BP, Omlor GJ, Millard SL, Clancy JP, Sawicki GS, Riekert K, Mayer-Hamblett N, Nichols DP; SIMPLIFY Study Group. Gifford AH, et al. Among authors: omlor gj. J Cyst Fibros. 2024 Sep 14:S1569-1993(24)00839-7. doi: 10.1016/j.jcf.2024.08.008. Online ahead of print. J Cyst Fibros. 2024. PMID: 39278759
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group. Flume PA, et al. Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10. Lancet Respir Med. 2021. PMID: 33581080
Genetic modifiers of liver disease in cystic fibrosis.
Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemková D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR; Gene Modifier Study Group. Bartlett JR, et al. JAMA. 2009 Sep 9;302(10):1076-83. doi: 10.1001/jama.2009.1295. JAMA. 2009. PMID: 19738092 Free PMC article.